Myriad Genetics to Present at the Cowen and Company 32nd Annual Health Care Conference
February 22 2012 - 4:15PM
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark
Capone, President, Myriad Genetic Laboratories, Inc., is scheduled
to present at the Cowen and Company 32nd Annual Health Care
Conference, at 8:00 a.m. Eastern Time on Tuesday, March 6, 2012.
The conference is being held at The Boston Marriott Copley Place
Hotel in Boston, Massachusetts.
The presentation will be available to interested parties through
a live webcast accessible on the investor relations section of
Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics, Inc. (Nasdaq:MYGN) is a leading molecular
diagnostic company dedicated to developing and marketing
transformative tests to assess a person's risk of developing
disease, guide treatment decisions and assess a patient's risk of
disease progression and disease recurrence. Myriad's portfolio
of nine molecular diagnostic tests are based on an understanding of
the role genes play in human disease and were developed with a
focus on improving an individual's decision making process for
monitoring and treating disease. With fiscal year 2011 annual
revenue of over $400 million and more than 1,000 employees, Myriad
is working on strategic directives, including new product
introductions, companion diagnostics, and international expansion,
to take advantage of significant growth opportunities. For
more information on how Myriad is making a difference, please visit
the Company's website: www.myriad.com.
CONTACT: Rebecca Chambers
Director, Investor Relations and Corporate Communications
(801) 584-1143
rchambers@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024